BREATHTEK UBT FOR H-PYLORI
LOE ApproachingNDAORALFOR SOLUTION
Approved
Sep 1996
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed Yesterday · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
BREATHTEK UBT FOR H-PYLORI is an oral diagnostic solution used to detect Helicobacter pylori infection in patients with gastrointestinal symptoms. It employs urea breath test methodology, a non-invasive diagnostic approach that measures bacterial urease activity. This diagnostic tool helps clinicians confirm H. pylori status prior to treatment initiation.
LOE Approaching
Product approaching loss of exclusivity with 30% competitive pressure; commercial team likely in transition or optimization mode rather than growth phase.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Zero linked job openings reflect the product's mature, late-stage lifecycle with minimal hiring. Career progression on BREATHTEK emphasizes defensive commercialization, payer negotiation, and diagnostic market expertise rather than launch excitement or innovation.
Diagnostic Product ManagerSales Representative (Diagnostics)
Worked on BREATHTEK UBT FOR H-PYLORI at Otsuka? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.